1-O-cis-9'-Octadecenyl-3-O-tritylglycerin | 82950-68-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: 1-O-cis-9'-Octadecenyl-3-O-tritylglycerin
• 英文别名: 1-oleyl-3-trityl glycerol；1-octadec-9c-enyloxy-3-trityloxy-propan-2-ol；1-[(Z)-octadec-9-enoxy]-3-trityloxypropan-2-ol
• CAS: 82950-68-3
• 化学式: C₄₀H₅₆O₃
• 分子量: 584.883
• InChiKey: ZZSOMXVPEYHPFT-KTKRTIGZSA-N

物化性质

• 沸点：
  683.0±55.0 °C(Predicted)
• 密度：
  1.002±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  11.9
• 重原子数：
  43
• 可旋转键数：
  24
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-O-cis-9'-Octadecenyl-3-O-tritylglycerin 在 四氮唑 、 sodium hydride 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 20.08h， 生成 Di-tert.-butyl 3-O-oleyl-2-O-methyl-rac-glycero-l-thiophosphate
  参考文献：
  名称：

  Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof

  摘要：

  该发明提供了抗凋亡组合物溶磷脂酸及其制备和使用方法。这种组合物还可以包含增强LPA作用的剂，包括蛋白质、脂质膜结构和聚合物，如聚乙二醇。该组合物还可以额外含有其他药用有效剂，如药物、抗生素、伤口愈合剂和抗氧化剂。

  公开号：

  US06949528B1
• 作为产物：
  描述：

  油醇 在 吡啶 、 盐酸 、 sodium hydride 、 三乙胺 、 sodium iodide 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 176.0h， 生成 1-O-cis-9'-Octadecenyl-3-O-tritylglycerin
  参考文献：
  名称：

  Compositions containing lysophosphatidic acids which inhibit apoptosis and uses thereof

  摘要：

  该发明提供了抗凋亡组合物溶磷脂酸及其制备和使用方法。这种组合物还可以包含增强LPA作用的剂，包括蛋白质、脂质膜结构和聚合物，如聚乙二醇。该组合物还可以额外含有其他药用有效剂，如药物、抗生素、伤口愈合剂和抗氧化剂。

  公开号：

  US06949528B1

文献信息

• Sterol-Modified Phospholipids: Cholesterol and Phospholipid Chimeras with Improved Biomembrane Properties
  作者：Zhaohua Huang、Francis C. Szoka

  DOI：10.1021/ja8065557

  日期：2008.11.19

  We synthesized a family of sterol-modified glycerophospholipids (SML) in which the sn-1 or sn-2 position is covalently attached to cholesterol and the alternative position contains an aliphatic chain. The SML were used to explore how anchoring cholesterol to a phospholipid affects cholesterol behavior in a bilayer. Notably, cholesterol in the SML retains the membrane condensing properties of free cholesterol regardless of the chemistry or position of its attachment to the glycerol moiety of the phospholipid. SMLs by themselves formed liposomes upon hydration and in mixtures between an SML and diacylglycerophospholipids (C14 to C18 chain length) the thermotropic phase transition is eliminated at the SML equivalent of about 30 mol % free cholesterol. Osmotic-induced contents leakage from SML (C14-C18) liposomes depends upon the linkage and position of cholesterol but in general is similar to that observed in 3/2 diacylphosphatidylcholine/cholesterol (mole ratio) liposomes. SML liposomes are exceptionally resistant to contents release in the presence of serum at 37 degrees C. This is probably due to the fact that SML exchange between bilayers is more than 100 fold less than the exchange rate of free cholesterol in the same conditions. Importantly, SML liposomes containing doxorubicin are as effective in treating the murine C26 colon carcinoma as Doxil, a commercial liposome doxorubicin formulation. SMLs stabilize bilayers but do not exchange and hence provide a new tool for biophysical studies on membranes. They may improve liposomal drug delivery in organs predisposed to the extraction of free cholesterol from bilayers, such as the skin, lung, or blood.
• Alunni-Bistocchi; Orvietani; Ricci, Il Farmaco, 1990, vol. 45, # 5, p. 499 - 509
  作者：Alunni-Bistocchi、Orvietani、Ricci、Binaglia、Orlando、Orlando

  DOI：——

  日期：——
• Reactions of Aliphatic Methanesulfonates. II. Syntheses of Long-Chain Di- and Trialkyl Glyceryl Ethers¹
  作者：Wolfgang J. Baumann、Helmut K. Mangold

  DOI：10.1021/jo01340a034

  日期：1966.2
• STEROL-MODIFIED AMPHIPHILIC LIPIDS
  申请人：The Regents of the University of California

  公开号：EP2219587A1

  公开（公告）日：2010-08-25
• Sterol-Modified Amphiphilic Lipids
  申请人：Szoka, JR. Francis C.

  公开号：US20110177156A1

  公开（公告）日：2011-07-21

  Disclosed are sterol-modified amphiphilic lipid compounds having two or more hydrophobic tails of which at least one is a sterol. Also disclosed are the processes for the synthesis of these compounds, compositions comprising such compounds, and the use of such compounds in delivery of an agent of interest, e.g., therapeutics, imaging agents, contrast materials for ultrasound applications, vaccines, biosensors, nutritional supplements and skin care products.